IMPEDIMED LIMITED — Board/Management Information 2009

Nov 5, 2009

6th November 2009

==> picture [109 x 104] intentionally omitted <==

----- Start of picture text ----- ASX : IPD----- End of picture text -----

ASX RELEASE

ImpediMed Appoints Vice President of Global Finance

ImpediMed CEO Greg Brown today announced the appointment of Ms Peggy Brooker as the Vice President of Global Finance. Ms Brooker will be located at the company’s San Diego facility in the United States. Mr Brown said the appointment reaffirmed ImpediMed’s strategic choice to establish the San Diego facility as the global operations hub, to support a focus on the group’s key growth market in the US.

Peggy has a wealth of experience in the finance sector, having been an audit partner for Ernst & Young LLP in the US as well as a Principal for Ernst & Young Australia, with experience spanning IPO’s, the implementation of strict financial controls and compliance. She also brings strong commercial experience, having been Vice President Finance, for Compass Aerospace Corporation. Mr Brown said the appointment of Peggy was another step in adding depth to the ImpediMed senior executive team, and a significant step forward in positioning ImpediMed as a stand out medical device manufacturer with the operational systems to comply with FDA, TGA and international standards.

Ms Brooker said she was excited to be joining the ImpediMed team and the opportunity to be part of the journey in positioning the company as a leader in the specialized medical device field focussing on cancer patient management.

“ImpediMed’s focus on improving quality of life, particularly for breast cancer patients, is very close to my heart. The opportunity to make a real difference is important,” she added.

Mr Brown said the appointment of the Vice President of Global Finance was part of an ongoing commitment to build a highly experienced senior executive team to manage the roll out of the company’s global launch.

Further announcements will follow as new appointments are made.

For further information contact:

Greg Brown ImpediMed CEO +61-7-3860-3700

1/2

L-Dex[®] is a trademark of ImpediMed Limited.

“ L-Dex[® ] values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L- Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L- Dex scale is not intended to diagnose or predict lymphoedema of an extremity”.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.

2/2